PEOPLE - VidaMed (US) president and Chief Executive Officer to resign:
This article was originally published in Clinica
James Heisch is to resign as president and CEO of VidaMed, a US manufacturer of advanced systems for the treatment of urological conditions. Mr Heisch said it was now time for VidaMed to recruit a seasoned medical-device executive who would lead the company in the launch of its transurethral ablation system (TUNA) for the treatment of benign prostatic hyperplasia. The system is already FDA-approved.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.